MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced the launch of the Shock-Less clinical trial. This trial will identify ways physicians can improve the quality of care for patients through optimal application of device-based tools designed to reduce unnecessary shocks in patients with implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy-defibrillator (CRT-D) devices. Specifically, the Shock-Less study aims to create evidence that will increase the use of programming tools that reduce unnecessary shocks including features on Medtronic devices, such as Medtronic’s exclusive Lead Integrity Alert™ (LIA) and Anti-Tachycardia Pacing (ATP) During Charging™.
